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orOBJECTIVES The aim of this study was to describe contemporary frequency, predictors, and outcomes of chronic total
occlusion (CTO) percutaneous coronary intervention (PCI) in the United States.
BACKGROUND CTO PCI can provide signiﬁcant clinical beneﬁts, yet there is limited information on its success and
safety in unselected patient populations.
METHODS We analyzed the frequency and outcomes of CTO PCI compared with non-CTO PCI in elective patients, and of
successful versus failed CTO PCI between July 1, 2009, and March 31, 2013, in the National Cardiovascular Data Registry
CathPCI Registry. Generalized estimating equations logistic regression modeling was used to generate independent
variables associated with procedural success and procedural complications.
RESULTS During the study period, CTO PCI represented 3.8% of the total PCI volume for stable coronary artery disease
(22,365 of 594,510). Overall, patients undergoing CTO PCI required greater contrast volume and longer ﬂuoroscopy time
and had lower procedural success (59% vs. 96%, p < 0.001) and higher major adverse cardiac event (1.6% vs. 0.8%,
p < 0.001) rates than non-CTO PCI patients. On multivariable analysis, several parameters (including older age, current
smoking, previous myocardial infarction, previous coronary artery bypass graft, previous peripheral arterial disease,
previous cardiac arrest, right coronary artery CTO target vessel, and less operator experience) were associated with a
lower likelihood of CTO PCI procedural success, whereas operators’ annual CTO PCI volume was associated with improved
success without a signiﬁcant increase in major complications.
CONCLUSIONS CTO PCI is currently performed infrequently in the United States for stable coronary artery disease and
is associated with lower procedural success and higher complication rates compared with non-CTO PCI. Procedural
success was associated with several patient factors and operator experience. (J Am Coll Cardiol Intv 2015;8:245–53)
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246C hronic total occlusions (CTOs) areencountered in 18.4% to 52% of pa-tients with coronary artery disease
(CAD) undergoing coronary angiography
(1–4). Although no randomized, controlled
trial of CTO percutaneous coronary interven-
tion (PCI) has been performed, observational
studies suggest that successful CTO PCI can
provide signiﬁcant clinical beneﬁt to pa-
tients, including symptom relief, improved
left ventricular function, reduced risk of ar-
rhythmias, and better tolerance of an acute
coronary syndrome (5). By contrast, failed
CTO PCI has been associated with anincreased risk of death and angina compared with
successful recanalization (6). In recent years, impor-
tant advances have occurred in CTO PCI techniques,
including the introduction and dissemination of the
retrograde approach (7–9), antegrade dissection/SEE PAGE 254re-entry techniques (10), and a systematic algorithmic
“hybrid” approach (11). As a result, some centers in
Europe (12), Japan (13), the United States (9,14–17),
and Canada (18) now consistently achieve technical
success rates >80%. Despite this progress, there is
an ongoing controversy on the relative value and
risks of CTO PCI, with this procedure being given a
Class IIa indication in the American Heart Associa-
tion/American College of Cardiology PCI guidelines
(19) and patients with CTOs being given lower ratings
in 5 of the 18 categories described in the PCI appropri-
ateness use criteria (20). This study sought to
describe contemporary risks and success of CTO PCI
and to compare these with non-CTO PCI to provide
an evidence-based foundation with which to better
evaluate the appropriateness of CTO PCI and docu-
ment opportunities to improve safety and use of
this potentially beneﬁcial procedure. We hypothe-
sized that CTO PCI is performed infrequently andde Medical, Terumo, Asahi, Abbott Vascular, Elsevier, Somahluti
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compared with non-CTO PCI.
METHODS
PATIENT POPULATION. The National Cardiovascular
Data Registry (NCDR) CathPCI Registry is an initiative
of the American College of Cardiology Foundation
and the Society for Cardiovascular Angiography and
Interventions. The registry receives data from more
than 1,000 participating U.S. hospitals, and catalogs
in-hospital data regarding patient characteristics,
clinical features, angiographic and procedural details,
and in-hospital outcomes for patients undergoing
diagnostic catheterizations and PCI. The registry uses
a standard dataset with pre-speciﬁed deﬁnitions
supplemented with data abstractor training, uniform
data entry and transmission requirements, and data
quality checks, although there is no core laboratory
adjudication of the angiographic parameters (21).
Details on the data collection process and the variable
deﬁnitions were published previously (21,22). For the
purpose of this study, we examined CathPCI Registry
patients with stable CAD undergoing PCI from July 1,
2009, to March 31, 2013.
DEFINITIONS OF CTO AND OUTCOMES. Since 2009, an
explicit, operator-deﬁned indication for attempting
CTO PCI has been implemented in NCDR CathPCI Re-
gistry version 4. This was used to identify patients
undergoing CTO PCI. The primary outcome of this
study was procedural success, deﬁned as <50% an-
giographic stenosis with Thrombolysis In Myocardial
Infarction ﬂow grade 3 after the procedure without
any major adverse cardiac event (MACE). A MACE
was deﬁned as the composite of death, urgent coro-
nary artery bypass graft (CABG) surgery, stroke, or
tamponade.
STATISTICAL ANALYSIS. Continuous variables are
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TABLE 1 Comparison of Patients With Stable Coronary Artery Disease Undergoing
CTO PCI Versus Those Undergoing Non-CTO PCI
Variable
All Patients
(N ¼ 594,510)
CTO PCI
(n ¼ 22,365)
Non-CTO PCI
(n ¼ 572,145) p Value
Demographic characteristics
Age, yrs 66.3  11.0 64.0  10.9 66.4  11.0 <0.001
Male 69 78 69 <0.001
White race 88 87 88 <0.001
Comorbidities
Hypertension 86 86 86 0.015
Dyslipidemia 85 88 85 <0.001
Diabetes mellitus 39 39 39 0.08
Current smoking 21 23 20 <0.001
Previous MI 31 38 31 <0.001
Previous PCI 46 48 46 <0.001
Previous CABG surgery 20 19 20 0.213
Cerebrovascular disease 13 11 13 <0.001
Peripheral arterial disease 14 14 14 0.034
Glomerular ﬁltration rate,
ml/min/1.73 m2
71.3  17.8 72.9  17.1 71.3  17.8 <0.001
Chronic lung disease 15 13 15 <0.001
Body mass index, kg/m2 30.3  15.0 30.5  13.9 30.3  15.0 0.035
CAD presentation
Symptoms <0.001
No angina 30 29 30
Atypical chest pain 9 7 10
Stable angina 61 64 60
Congestive heart failure
within 2 weeks
9 10 9 <0.001
PCI outcomes
Procedural success 94 59 96 <0.001
MACE 0.8 1.6 0.8 <0.001
Death 0.3 0.4 0.3 <0.001
Urgent CABG surgery 0.4 0.8 0.4 <0.001
Stroke 0.1 0.1 0.1 0.045
Tamponade 0.1 0.3 0.1 <0.001
MI 1.9 2.7 1.9 <0.001
RBC transfusion 1.9 2.7 1.9 <0.001
Contrast volume 189.1  92.3 243.8  124.7 187.0  90.1 <0.001
Fluoroscopy time 15.0  12.4 29.9  20.8 14.5  11.6 <0.001
Values are mean  SD or %.
CABG ¼ coronary artery bypass graft; CAD ¼ coronary artery disease; CTO PCI ¼ chronic total occlusion
percutaneous coronary intervention; MACE ¼ major adverse cardiac event(s); MI ¼ myocardial infarction;
PCI ¼ percutaneous coronary intervention; RBC ¼ red blood cell.
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247variables were reported as percentages. The baseline
characteristics, PCI procedural ﬁndings, and in-
hospital outcomes were compared between patients
with stable CAD who underwent CTO versus non-CTO
PCI. A second set of comparisons was performed
among the CTO procedures and compared the char-
acteristics of successful versus failed CTO PCI. Com-
parisons between groups were performed using
Pearson chi-square tests for all categorical variables
and Wilcoxon tests for all continuous variables.
Hierarchical multivariable logistic regression ana-
lyses were performed to determine variables asso-
ciated with procedural success and complications of
CTO PCI. The following parameters from the NCDR
data collection formswere entered into themodel: age,
sex, Caucasian race, body mass index, no medical in-
surance, glomerular ﬁltration rate calculated using the
Modiﬁcation of Diet in Renal Disease study equation,
smoking, hypertension, dyslipidemia, family history
of CAD, previous myocardial infarction (MI), previous
heart failure, previous valve surgery, previous CABG
surgery, currently on dialysis, previous cardiovascular
disease, previous peripheral arterial disease, chronic
liver disease, diabetes mellitus, heart failure within
the previous 2 weeks, previous cardiogenic shock,
previous cardiac arrest, CTO target vessel (left main
coronary artery, left anterior descending coronary ar-
tery, left circumﬂex coronary artery) average CTO PCI
volume during the previous year, and average elective
PCI volume during the previous year.
All tests were 2-sided, and p < 0.05 was considered
statistically signiﬁcant. All analyses were performed
using SAS software (version 9.2, SAS Institute, Cary,
North Carolina) by Saint Luke’s Mid America Heart
Institute (Kansas City, Missouri). The authors had full
access to the data and take responsibility for its
integrity. All authors have read and agree to the paper
as written.
RESULTS
PATIENT AND PROCEDURAL CHARACTERISTICS OF
CTO PCI IN STABLE CAD. During the study period,TABLE 2 Success and MACE Rates of CTO PCI Over Time
Outcome
Total
(N ¼ 22,365)
2009
(n ¼ 2,695)
2010
(n ¼ 6,373)
2011
(n ¼ 6,161)
2012
(n ¼ 5,650)
2013
(n ¼ 1,486) p Value
CTO PCI as percentage of
total PCI volume
22,365 of
594,510 (3.8)
2,695 of
84,483 (3.2)
6,373 of
183,649 (3.5)
6,161 of
160,072 (3.8)
5,650 of
135,331 (4.2)
1,486 of
30,975 (4.8)
<0.001
Procedural success 13,077 (58.5) 1,495 (55.5) 3,637 (57.1) 3,645 (59.2) 3,380 (59.8%) 920 (61.9) <0.001
MACE 357 (1.6) 50 (1.9) 103 (1.6) 104 (1.7) 81 (1.4) 19 (1.3) 0.108
Values are n (%).
Abbreviations as in Table 1.
FIGURE 1 Relative Frequency of CTO PCI
Proportion of chronic total occlusion percutaneous coronary intervention (CTO PCI) cases
among centers participating in the NCDR (National Cardiovascular Data Registry).
FIGURE 2 CTO PCI
Proportion of chroni
(n ¼ 60) (A) and sit
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248CTO PCI represented 3.8% of the total PCI volume for
stable CAD (22,365 of 594,510), with marked variation
in use across centers (0% to 44%; interquartile range
1.2% to 4.5%) (Tables 1 and 2, Figure 1). At 1,387 sitesSuccess Rates
c total occlusion percutaneous coronary intervention (CTO PCI) cases among
es at which at least 30 CTO PCI procedures were performed during the studyincluded in the analysis, CTO PCI was never attemp-
ted at 234 (17%). Marked variation was also noted
among operators (interquartile range 0.3% to 4.9%).
CTO PCI represented a low but increasing propor-
tion of the total PCI volume for stable coronary
artery disease, from 3.2% in 2009 to 4.8% in 2013
(Table 2), in stable CAD PCI procedures. Compared
with patients undergoing non-CTO PCI, those un-
dergoing CTO PCI were younger and more likely to be
men, to have had a previous MI or PCI or left ven-
tricular dysfunction, and to undergo staged PCI. They
were less likely to have cerebrovascular disease,
chronic lung disease, and peripheral arterial disease
(Table 1).
CTO PCI PROCEDURAL SUCCESS. Patients undergo-
ing CTO PCI had lower procedural success compared
with non-CTO PCI (59% vs. 96%, p < 0.001), with
marked variability across centers and operators
(Figure 2). Procedural success among operators
performing <5, 5 to 10, and >10 CTO PCI procedures
per year was 53%, 62%, and 75%, respectively (p <
0.001) (Table 3). Procedural success for the 8 high-
volume operators was 81%. Patients undergoing CTO
PCI also required higher contrast volume and longer
ﬂuoroscopy time (Table 1). Procedural success signif-
icantly increased over time from 55.5% in 2009 to
61.9% in 2013 (p < 0.001) (Table 2).operators performing more than 10 CTO PCI procedures per year
period (B).
TABLE 3 Procedural Success and MACE Rates as a Function of Annual CTO PCI Volume
Outcome
Total
(N ¼ 22,225)
<5 CTO PCI
per Year
(n ¼ 14,934)
5–10 CTO PCI
per Year
(n ¼ 2,881)
>10 CTO PCI
per Year
(n ¼ 4,410) p Value
Procedural success 13,010 (58.5) 7,934 (53.1) 1,788 (62.1) 3,288 (74.6) <0.001
MACE 356 (1.6) 260 (1.7) 34 (1.2) 62 (1.4) 0.050
Values are n (%).
Abbreviations as in Table 1.
TABLE 4 Comparison of Successful Versus Failed CTO PCI Cases
Variable
Successful
CTO PCI
(n ¼ 13,077)
Failed
CTO PCI
(n ¼ 9,288) p Value
Demographic characteristics
Age, yrs 63.6  11.0 64.7  10.8 <0.001
Male 78 78 0.685
White race 87 86 0.053
Comorbidities
Hypertension 85 86 0.009
Dyslipidemia 88 88 0.206
Diabetes mellitus 38 40 <0.001
Current smoking 21 25 <0.001
Previous MI 37 40 <0.001
Previous PCI 48 49 0.397
Previous CABG surgery 18 20 <0.001
Cerebrovascular disease 11 13 <0.001
Peripheral arterial disease 13 16 <0.001
Glomerular ﬁltration rate,
ml/min/1.73 m2
73.0  17.1 72.8  17.2 0.355
Chronic lung disease 12 15 <0.001
Body mass index, kg/m2 30.4  16.5 30.6  9.0 0.459
CAD presentation
Symptoms <0.001
No angina 28 30
Atypical chest pain 6 9
Stable angina 66 61
Congestive heart failure within
2 weeks
10 11 0.015
CTO target vessel
Right coronary artery 44 47 <0.001
Left main artery 1 0.5 <0.001
Left anterior descending artery 33 27 <0.001
Left circumﬂex artery 24 26 <0.001
PCI outcomes
Procedural success 100 0 <0.001
In-hospital MACE 0 3.8 <0.001
Death 0 1.1 <0.001
Urgent CABG surgery 0 1.9 <0.001
Stroke 0 0.3 <0.001
Tamponade 0 0.8 <0.001
MI 2.8 2.5 0.212
RBC transfusion 1.2 2.2 <0.001
Contrast volume, ml 258.1  124.8 223.5  121.9 <0.001
Fluoroscopy time, min 30.1  21.1 29.6  20.5 <0.001
Values are mean  SD or %.
Abbreviations as in Table 1.
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249Compared with patients in whom CTO PCI failed,
those in whom CTO PCI was successful were younger
and more likely to be current smokers and to have left
anterior descending artery CTO. They were less likely
to have had a previous MI, diabetes, cerebrovascular
or peripheral arterial disease, chronic lung disease,
and previous CABG (Table 4). Successful CTO PCI cases
required more contrast administration but had similar
ﬂuoroscopy time. On multivariable analysis, several
parameters (older age, current smoking, previous MI,
previous CABG, previous peripheral arterial disease,
previous cardiac arrest, right coronary artery CTO
target vessel, and less operator experience) were
associated with a lower likelihood of CTO PCI pro-
cedural success (Figure 3). Larger operator annual
volume in CTO PCI was associated with higher proce-
dural success rates (Figure 4, Table 3). However, only 8
operators performed 50 or more CTO PCI per year.
CTO PCI COMPLICATIONS. Patients undergoing CTO
PCI had higher MACE rates compared with non-CTO
PCI procedures (1.6% vs. 0.8%, p < 0.001) (Table 1),
with a trend toward a decreased MACE rate over time
(Table 2). Among operators performing more than 10
CTO PCIs per year (n ¼ 60), the median MACE rate
was 1% (interquartile range: 0% to 2%). At sites where
more than 30 CTO PCIs were performed during the
study period (n ¼ 510), the median MACE rate was 0%
(interquartile range, 0% to 3%). Compared with pa-
tients in whom CTO PCI was complicated by a MACE,
those in whom CTO PCI did not result in a MACE were
younger, more likely to have had previous PCI and
previous CABG surgery, and less likely to have a his-
tory of cerebrovascular disease or chronic lung dis-
ease (Table 5). Higher CTO PCI operator volume
was associated with lower MACE rates (Figure 4).
On multivariable analysis, several parameters (but
not operator CTO PCI annual volume [Figure 4])
were associated with higher likelihood of MACE
(Figure 5).
DISCUSSION
To the best of our knowledge, this is the largest study
performed to date, from a prospective PCI database
providing detailed information on the frequency and
outcomes of contemporary CTO PCI. Analyses of the
CathPCI Registry demonstrate that CTO PCI is infre-
quently performed in the United States, although its
frequency has been increasing over time; is associated
with lower procedural success and higher complica-
tion rates compared with non-CTO PCI for stable CAD;
and procedural success and MACE are associated with
both patient factors and operator experience.
FIGURE 3 Factors Associated With CTO PCI Success
Forest plot of variables associated with chronic total occlusion percutaneous coronary
intervention (CTO PCI) success. Avg ¼ average; BMI ¼ body mass index; CABG ¼ coronary
artery bypass graft; CAD ¼ coronary artery disease; CardShock ¼ cardiac shock; CLD ¼
chronic liver disease; CVD ¼ cardiovascular disease; DM ¼ diabetes mellitus; Dyslip ¼
dyslipidemia; GFR ¼ glomerular ﬁltration rate; HF ¼ heart failure; HTN ¼ hypertension;
Hx ¼ history; LAD ¼ left anterior descending artery; LCX ¼ left circumﬂex artery; LM ¼ left
main; MI ¼ myocardial infarction; PAD ¼ peripheral arterial disease; proc ¼ procedure;
RR ¼ relative risk.
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250FREQUENCY OF CTO PCI. Our study demonstrates
that CTO PCI accounts for a small proportion of PCIs
for stable CAD currently performed in the United
States (3.8%), although its frequency has been
increasing slightly over time (it represented 3.2% of all
PCIs in 2009 vs. 4.8% in 2013). Although early reports
of CTO prevalence from the NCDR suggested that it
was present in only 5.5% of cases (23), prospective
registries that explicitly examined the prevalence of
CTOs documented rates of 18.4% to 52% (1–4).
Similar to previous studies (1), there is wide vari-
ability in the proportion of CTO PCIs (Figures 1 and 2)
performed at various centers. Given the high preva-
lence of CTOs, the overall proportion of CTO PCI is
very low. Potential explanations for the disparity
between the prevalence and treatment of CTOs with
PCI include the following: 1) CTOs are often associ-
ated with extensive CAD, necessitating CABG surgery
referral in many patients; 2) variation in localexpertise and comfort with performing CTO PCI; and
3) limited evidence on the risk/beneﬁt ratio of CTO
PCI leading to frequent treatment with medical ther-
apy alone in many patients with CTOs.
Comparison of CTO PCI and non-CTO PCI. We found
important differences in the outcomes of CTO
compared with non-CTO PCI: CTO PCI was associated
with signiﬁcantly lower procedural success and higher
complication rates (although the overall rate of MACE
was relatively low [1.6%] in patients undergoing CTO
PCI). This marked discrepancy in outcomes is likely
related to the higher technical difﬁculty of CTO PCI,
higher CAD burden of patients with CTOs, and limited
local expertise with the procedure. However, the
alternative revascularization strategy to CTO PCI in
many patients is CABG surgery, which may also carry
increased procedural risk in patients with CTOs (24).
Moreover, many patients undergoing CTO PCI may
not be good candidates for CABG surgery; for
example, patients with a previous CABG represented
w20% of the NCDR CTO PCI cohort and 37% of a
contemporary U.S. CTO PCI registry (14). Given the
high rates of saphenous vein graft failure (25) and the
increased risk of redo CABG surgery (26), CTO PCI may
be the preferred revascularization modality in the
majority of patients who have had a previous CABG.
CTO PCI procedura l success . Several factors were
associated with procedural success in our study,
related to both the patient (age, smoking, previous
MI, previous CABG, previous peripheral arterial dis-
ease, previous cardiac arrest, CTO target vessel), and
the operator (CTO PCI volume). Although the overall
success rate remained low during the study period,
signiﬁcant improvement occurred between the ﬁrst
(2009, 55.5%) and last (2013, 61.9%) years of the study
(Table 2).
Older age is likely associated with more advanced
coronary atherosclerosis and greater coronary artery
calciﬁcation. Previous CABG surgery has been associ-
ated with lower procedural success rates (27), likely
due to more extensive calciﬁcation and negative
remodeling (28) and possible distortion of the
native coronary artery anatomy from the graft anas-
tomoses. Of 1,363 patients in a multicenter CTO regis-
try, 37% had previous CABG surgery and those patients
were older, hadmore comorbidities, were treatedmore
frequently with the retrograde approach (46.7% vs.
27.1%, p<0.001), and had lower technical success rates
(79.7% vs. 88.3%, p ¼ 0.015), but similar major
complication rates (2.1% vs. 1.5%, p ¼ 0.392) compared
with patients without previous CABG (27).
The signiﬁcant increase in CTO PCI success rates
with increasing CTO PCI volume (Figure 4) supports
FIGURE 4 Operator CTO PCI Volume Association With Procedural Success
and Complications
Procedural success and major adverse cardiac event (MACE) rates as a function of annual
operator chronic total occlusion percutaneous coronary (CTO PCI) volume.
FIGURE 5 Factors Associated With CTO PCI Complications
Forest plot of variables associated with MACE. Abbreviations as in Figures 3 and 4.
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251performing CTO PCI by experienced operators at
centers with high CTO PCI volume, where a 5% in-
crease in success for each 10 CTO PCI procedures
performed per year was observed. Of note, the overall
PCI volume was not associated with success in CTO
PCI (Figure 3), suggesting that performing large
numbers of non-CTO PCIs is not associated with more
success in performing CTO PCI. This is not surprising,
given that CTO PCI is a fundamentally different pro-
cedure, requiring different techniques and skills
compared with non-CTO PCI. Both subintimal
crossing techniques (10,29) and the retrograde
approach (7,29) are not used in non-CTO PCI, and
require time and practice to learn and master.
Improved training pathways in CTO PCI could reduce
the marked variation in procedural outcomes. More-
over, operator experience with CTO PCI can result,
not only in higher success rates, but also in lower
ﬂuoroscopy and contrast use (30). There appeared to
be no upper limit in CTO PCI success rates with
increased CTO PCI volume (Figure 4), suggesting that
continuous improvement is possible, even among
high-volume CTO PCI operators.
CTO PCI COMPLICATIONS. A recent systematic re-
view of published studies reported low and
decreasing rates of CTO PCI complications over time,
despite increasing success rates (31). In our study,
the risk of complications with CTO PCI was higher
than with non-CTO PCI, which was in part related to
higher baseline risk proﬁles of CTO patients and
the use of advanced CTO crossing techniques. Pre-
vious PCI and previous CABG surgery were associ-
ated with lower risks of complications; however,
comorbidities (e.g., history of cerebrovascular dis-
ease or chronic lung disease) were associated with
higher risk. Operator CTO PCI volume was not
associated with lower complication rates on multi-
variable analysis, possibly because high-volume CTO
operators may perform more complex CTO PCI pro-
cedures, which could not be well characterized in
this cohort, given the absence of detailed angio-
graphic descriptions of CTOs in the NCDR Registry.
This stable complication rate in the spectrum of
various procedural volumes still supports the per-
formance of CTO PCI among high-volume operators
and centers, because procedural success was higher
in those centers without incurring a penalty in terms
of procedural complications (i.e., the risk/beneﬁt
ratio was higher).
STUDY IMPLICATIONS. Our study suggests that CTO
PCI may be underused, because it is infrequently
performed (only 3.8% of all PCI cases in the United
States were CTO PCI during the study period), despite
TABLE 5 Comparison of CTO PCI Cases With and Without
Periprocedural Complications
Variable
Periprocedural
Complications
(n ¼ 357)
No Periprocedural
Complications
(n ¼ 22,008) p Value
Demographic
characteristics
Age, yrs 65.6  11.6 64.0  10.9 0.006
Male 78 78 0.893
White race 88 87 0.446
Comorbidities
Hypertension 82 86 0.087
Dyslipidemia 80 88 <0.001
Diabetes mellitus 35 39 0.114
Current smoking 23 23 0.779
Previous MI 35 38 0.186
Previous PCI 35 49 <0.001
Previous CABG 11 19 <0.001
Cerebrovascular
disease
17 11 <0.001
Peripheral arterial
disease
17 14 0.056
Glomerular
ﬁltration rate,
ml/min/1.73 m2
69.7  18.9 73.0  17.1 <0.001
Chronic lung disease 19 13 <0.001
Body mass index,
kg/m2
30.2  9.0 30.5  14.0 0.689
CAD presentation
Symptoms <0.001
No angina 41 29
Atypical chest pain 11 7
Stable angina 48 64
Congestive heart failure
within 2 weeks
18 10 <0.001
PCI outcomes
Procedural success 0 59 <0.001
MACE
Death 28 0 <0.001
Urgent CABG 51 0 <0.001
Stroke 9 0 <0.001
Tamponade 20 0 <0.001
Myocardial
infarction
9.3 2.6 <0.001
RBC transfusion 26.3 1.2 <0.001
Contrast volume, ml 252.7  148.2 243.6  124.3 0.171
Fluoroscopy time, min 34.7  29.2 29.8  20.7 <0.001
Values are mean  SD or %.
Abbreviations as in Table 1.
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252the high prevalence of coronary CTOs (1–4). Our study
also suggests that CTO PCI is currently associated
with lower success and higher complication rates
than non-CTO PCI, emphasizing the importance of
dedicated CTO PCI training. Given the association of
higher CTO PCI volume with higher success rates, it
may be worthwhile, from a societal perspective, to
concentrate CTO PCI at high-volume centers and inoperators committed to developing and maintaining
CTO PCI programs. Such programs would provide
operators with the necessary equipment and support
that are critical for achieving high success rates while
maximizing safety (29,32).
STUDY LIMITATIONS. Our ﬁndings should be inter-
preted in the context of several potential limitations.
Participation in the CathPCI Registry is voluntary, and
therefore, the results may not be representative of the
entire U.S. population, although the number of
participating sites is large. In the CathPCI Registry,
there is no core laboratory assessment of the patients’
angiograms and composite assessments of the coro-
nary anatomy, such as the SYNTAX (Synergy between
PCI with Taxus and Cardiac Surgery) score, proximal
cap ambiguity, lesion length, tortuosity and calciﬁ-
cation, quality of the distal vessel, and the presence
and quality of collateral circulation, which were not
available. CathPCI Registry data are collected for in-
hospital stay only; as such, differences in long-term
outcomes of patients who underwent CTO versus
those who underwent non-CTO PCI could not be
assessed. Moreover, the long-term outcomes after use
of the novel CTO crossing techniques (such as limited
antegrade dissection/re-entry and the retrograde
approach) have had limited study (33). Also prospec-
tive, randomized, controlled clinical trials are needed
to accurately assess the risks and beneﬁts of CTO PCI
compared with optimal medical therapy alone. It is
not known what initiated the decision to intervene in
a CTO; therefore, unmeasured confounding variables
could be responsible for some of the variability in in-
hospital outcomes (success and MACE rates) after
CTO PCI.
CONCLUSIONS
CTO PCI is currently infrequently performed and
has lower success and higher complication rates
compared with non-CTO PCI. However, higher oper-
ator experience was associated with higher success
rates. Addressing the gap between what can
be achieved in experienced CTO PCI centers and
less experienced centers holds great promise for
improving outcomes in this complex patient and lesion
group.
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